18 September, 2017
Kcg reported 0.01% in NewLink Genetics Corp (NASDAQ:NLNK). Stifel Nicolaus' target price indicates a potential upside of 64.12% from the stock's current price. Recently, investment analysts covering the stock have updated the mean rating to 2.2.
A number of other equities research analysts also recently issued reports on NLNK. Northwest Wealth Management LLC now owns 58,022 shares of the biotechnology company's stock valued at $426,000 after acquiring an additional 1,740 shares during the period. ValuEngine raised NewLink Genetics Corporation from a sell rating to a hold rating in a report on Friday, May 19th.
05/10/2016 - NewLink Genetics Corporation had its "buy" rating reiterated by analysts at Mizuho. Analysts are turning out to be more optimistic than before, with 3 of analysts who cover NewLink Genetics Corporation (NASDAQ:NLNK) advice adding it to buy candidate list. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the stock.
14-day Williams %R for NewLink Genetics Corporation (NASDAQ:NLNK) moved to around 12.54.
01/07/2015 - NewLink Genetics Corporation was upgraded to "outperform" by analysts at Zacks. NewLink Genetics Corporation has a 52-week low of $5.90 and a 52-week high of $25.17. Moving toward the technical facts, its current distance from 20-Day Simple Moving Average is 114.03% and standing 121.96% away from 50-Day Simple Moving Average while traded up 32.63% from 200-Day Simple Moving Average. The corporation has a market cap of US$41.86 Million. For the past 5 years, the company's revenue has grown 80.4%, while the company's earnings per share has grown 0.3%. This continues to be an interesting story, and we look forward to updating it again soon on NewLink Genetics Corporation.
Many analysts have provided their estimated foresights on NewLink Genetics Corporation Earnings, with 5 analysts believing the company would generate an Average Estimate of $-0.77.
NewLink Genetics Corporation (NLNK) showed volatility of 24.77% over the past week.
TRADEMARK VIOLATION WARNING: This piece was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. The stock of NewLink Genetics Corp (NASDAQ:NLNK) has "Buy" rating given on Monday, July 10 by Stifel Nicolaus. Knoll Capital Management LP bought a new position in NewLink Genetics Corporation during the third quarter valued at $1,504,000.
NewLink Genetics Corporation (NLNK) stock directed 65.90% toward a higher level throughout a year ago and swapped 154.82% toward a strong spot during past one month. Eqis Capital Management upgraded its holdings in NewLink Genetics Corporation by 0.6% through out the 2nd period. Considering that the stock daily volume of 10.1 million shares, this represents a pretty noteworthy trading in volume size. Brandes Investment Partners LP acquired a new position in shares of NewLink Genetics Corporation in the first quarter worth $221,000. Volume in the last session has increased compared with CDW's average trading volume. American International Group Inc. lifted its holdings in NewLink Genetics Corporation by 7.1% during the 1st quarter. The Manufacturers Life Insurance Company grew its stake in shares of NewLink Genetics Corporation by 3.0% during the 2nd quarter. Finally, Northwest Wealth Management LLC lifted its holdings in NewLink Genetics Corporation by 3.1% during the 2nd quarter. However, if the CDW shares go below $59.12 then it would indicate a much weaker market for the company.
Its additional HyperAcute Cellular Immunotherapy product candidates in clinical development include tergenpumatucel-L and dorgenmeltucel-L for patients with advanced lung cancer and melanoma, respectively.
